Stryde Research is heading to ACR Convergence 2026, the American College of Rheumatology’s annual meeting, in Orlando, Florida. We will be on the exhibit floor at booth 2633 from Sunday, November 8 through Tuesday, November 10, with four members of our team ready to talk rheumatology, autoimmune research, and cell and gene therapy. Come find …
Read more “Stryde Research is exhibiting at ACR Convergence 2026 in Orlando”
Stryde Research sites were recently named among the top enrolling sites in two ongoing studies: a multinational lupus clinical trial and an atopic dermatitis (eczema) study. Both recognitions came from study teams in updates to participating investigators. Each ranking counts patients enrolled. What they reflect is how our sites operate, and the trust patients already …
Read more “Stryde Research named a top enrolling site, again”
Stryde Research will attend the Global Site Solutions Summit in Orlando, Florida, from October 15 to 18, 2026. Dr. Haein Kim and Edward Olko from our team will be there to meet with sponsors and CROs who are planning site selection or managing studies that are behind on enrolment. Stryde runs clinical research sites inside …
Read more “Stryde Research at the Global Site Solutions Summit 2026”
Stryde Research is heading to Cell and Gene Meeting on the Mesa, October 5 to 7 in Phoenix, Arizona. Edward Olko, our head of business development, will be there all three days to meet with sponsors, CROs, and physicians working in cell and gene therapy. If you’re attending, come find him and say hello. Event …
Read more “Stryde Research is heading to Cell and Gene Meeting on the Mesa 2026”
Stryde Research is joining the Lupus Foundation of America’s Walk to End Lupus Now on Saturday, September 26th at Klyde Warren Park in Dallas. We will have a table on site, a team walking the route, and giveaways for anyone who stops by. Come find us and say hello. Event details Find our table Look …
Read more “Stryde Research is walking at the 2026 Dallas Walk to End Lupus Now”
In a global lupus study, Stryde delivered one of only a handful of randomizations achieved anywhere so far.
Our lupus team joined the Lupus Foundation of America’s conference in Dallas to connect with patients and advocates.
One of our sites became the first in the world to enroll and dose a patient in a Phase 2 angiokeratoma study.
Stryde randomized its first patient in a skin cancer study testing a new, less invasive injection-based treatment.